Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, w...
Uložené v:
| Vydané v: | PharmacoEconomics Ročník 42; číslo 4; s. 447 - 461 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Cham
Springer International Publishing
01.04.2024
Springer Nature B.V |
| Predmet: | |
| ISSN: | 1170-7690, 1179-2027, 1179-2027 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Objective
Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB–LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective.
Methods
PrEP-eligible adults entered the Markov model receiving CAB–LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%.
Results
The model estimated that the CAB–LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage.
Conclusions
Our analysis suggests that initiating CAB–LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection. |
|---|---|
| AbstractList | Objective
Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB–LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective.
Methods
PrEP-eligible adults entered the Markov model receiving CAB–LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%.
Results
The model estimated that the CAB–LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage.
Conclusions
Our analysis suggests that initiating CAB–LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection. Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB-LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective. PrEP-eligible adults entered the Markov model receiving CAB-LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%. The model estimated that the CAB-LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage. Our analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection. Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB-LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective.OBJECTIVECabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB-LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective.PrEP-eligible adults entered the Markov model receiving CAB-LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%.METHODSPrEP-eligible adults entered the Markov model receiving CAB-LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%.The model estimated that the CAB-LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage.RESULTSThe model estimated that the CAB-LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per QALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage.Our analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection.CONCLUSIONSOur analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection. Objective Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on the HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction in HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in men who have sex with men (MSM), transgender women (TGW), and cisgender women. A decision-analytic model was developed to assess the lifetime cost-effectiveness of initiating CAB-LA versus generic oral FTC/TDF for HIV PrEP in the USA from a healthcare sector perspective. Methods PrEP-eligible adults entered the Markov model receiving CAB-LA or FTC/TDF and could continue initial PrEP, transition to a second PrEP option, or discontinue PrEP over time. Efficacy was taken from the HPTN 083 and HPTN 084 clinical trials. Individuals who acquired HIV-1 infection incurred lifetime HIV-related costs, could transmit HIV onwards, and could develop PrEP-related resistance mutations. Input parameter values were obtained from public and published sources. Model outcomes were discounted at 3%. Results The model estimated that the CAB-LA pathway prevented 4.5 more primary and secondary HIV-1 infections per 100 PrEP users than the oral PrEP pathway, which yielded 0.2 fewer quality-adjusted life-years (QALYs) lost per person. Additional per-person lifetime costs were $9476 (2022 US dollars), resulting in an incremental cost-effectiveness ratio of $46,843 per Q ALY gained. Results remained consistent in sensitivity and scenario analyses, including in underserved populations with low oral PrEP usage. Conclusions Our analysis suggests that initiating CAB-LA for PrEP is cost-effective versus generic daily oral FTC/TDF for individuals at risk of acquiring HIV-1 infection. |
| Author | Fraysse, Jeremy Mellott, Claire E. Metzner, Aimee A. Brogan, Anita J. Davis, Ashley E. Oglesby, Alan K. |
| Author_xml | – sequence: 1 givenname: Anita J. orcidid: 0000-0002-9003-994X surname: Brogan fullname: Brogan, Anita J. email: abrogan@rti.org organization: RTI Health Solutions – sequence: 2 givenname: Ashley E. orcidid: 0000-0002-7500-6533 surname: Davis fullname: Davis, Ashley E. organization: RTI Health Solutions – sequence: 3 givenname: Claire E. orcidid: 0000-0003-0513-0990 surname: Mellott fullname: Mellott, Claire E. organization: RTI Health Solutions – sequence: 4 givenname: Jeremy orcidid: 0000-0002-7608-1391 surname: Fraysse fullname: Fraysse, Jeremy organization: ViiV Healthcare – sequence: 5 givenname: Aimee A. orcidid: 0000-0002-2702-3865 surname: Metzner fullname: Metzner, Aimee A. organization: ViiV Healthcare – sequence: 6 givenname: Alan K. orcidid: 0000-0002-8121-4478 surname: Oglesby fullname: Oglesby, Alan K. organization: ViiV Healthcare |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38267806$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV1vFCEYhSemxn7oH_DCkHjjzSgfw8BcmWajtskmmmi9JSy8zNLMwgrMpvvvpd3Wj170ggB5n3Ny4Jw2RyEGaJrXBL8nGIsPucNUsBbTugjraLt_1pwQIoaW1sHR3Rm3oh_wcXOa8zXGuGeCvmiOmaS9kLg_aewi5tKCc2CK30GAnFF0aKFXscCY9M4ntIxhbM_rPIzIxYQuLn-ibwlauNnGPCeol7hd7yd94zPyAZU1oKvgC1j0vegC-WXz3Okpw6v7_ay5-vzpx-KiXX79crk4X7amE7zUpGa1woLbQVorOwd84JJhY4E5GKxkznBpBNPCDR0Ba6wBybHte4cHLgw7az4efLfzalPnEErSk9omv9Fpr6L26v9J8Gs1xp0ieGBC9KQ6vLt3SPHXDLmojc8GpkkHiHNWdCCSE0z7vqJvH6HXcU6hvq9SXAguOZWVevNvpD9ZHhqogDwAJsWcEzhlfP00H28T-qlGU7dlq0PZqpat7spW-yqlj6QP7k-K2EGUKxxGSH9jP6H6DR6Dvk8 |
| CitedBy_id | crossref_primary_10_1007_s41669_025_00599_7 crossref_primary_10_1016_j_jorep_2025_100754 crossref_primary_10_1097_QAI_0000000000003602 |
| Cites_doi | 10.1016/S1473-3099(14)70847-3 10.1371/journal.pone.0108742 10.1086/597095 10.1056/NEJMoa1402269 10.1056/NEJMp1405158 10.1007/s40273-022-01231-w 10.1371/journal.pmed.1003670 10.1016/j.annepidem.2017.02.003 10.7326/M21-1548 10.1016/S0140-6736(22)00538-4 10.1056/NEJMoa2101016 10.1007/s41669-020-00209-8 10.1097/QAI.0b013e3182973966 10.1093/cid/civ664 10.1016/S0140-6736(20)31065-5 10.1093/cid/ciz894 10.7326/M19-3478 10.1002/jia2.25433 10.1371/journal.pone.0020200 10.9745/GHSP-D-13-00010 10.1001/jama.2016.12195 10.1097/MLR.0b013e31815c31a7 10.1007/s40273-015-0327-2 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). Copyright Springer Nature B.V. Apr 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: Copyright Springer Nature B.V. Apr 2024 |
| DBID | C6C AAYXX CITATION NPM 3V. 4T- 7WY 7WZ 7X7 7XB 87Z 88C 88E 88G 8C1 8FI 8FJ 8FK 8FL ABUWG AFKRA AZQEC BENPR BEZIV CCPQU DWQXO FRNLG FYUFA F~G GHDGH GNUQQ K60 K6~ K9. L.- L.0 M0C M0S M0T M1P M2M PHGZM PHGZT PJZUB PKEHL PPXIY PQBIZ PQBZA PQEST PQQKQ PQUKI PSYQQ Q9U 7X8 5PM |
| DOI | 10.1007/s40273-023-01342-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Docstoc ABI/INFORM Collection ABI/INFORM Global (PDF only) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ABI/INFORM Global (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ABI/INFORM Collection (Alumni) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central Business Premium Collection ProQuest One Community College ProQuest Central Korea Business Premium Collection (Alumni) ProQuest Health & Medical Collection ABI/INFORM Global (Corporate) Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Business Collection (Alumni Edition) ProQuest Business Collection ProQuest Health & Medical Complete (Alumni) ABI/INFORM Professional Advanced ABI/INFORM Professional Standard ABI/INFORM Global ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Business ProQuest One Business (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ABI/INFORM Global (Corporate) ProQuest Business Collection (Alumni Edition) ProQuest One Business ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ABI/INFORM Complete ProQuest Central ABI/INFORM Professional Advanced ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ABI/INFORM Professional Standard ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ABI/INFORM Complete (Alumni Edition) Business Premium Collection ABI/INFORM Global ProQuest Public Health ABI/INFORM Global (Alumni Edition) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Business Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition Docstoc ProQuest Health Management (Alumni Edition) ProQuest One Business (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Business Premium Collection (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ABI/INFORM Global (Corporate) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Economics Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1179-2027 |
| EndPage | 461 |
| ExternalDocumentID | PMC10937761 38267806 10_1007_s40273_023_01342_y |
| Genre | Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: ViiV Healthcare, Inc. |
| GroupedDBID | --- -5G -BR -EM 0R~ 0VX 123 199 29O 36B 3V. 4.4 406 53G 6I2 7WY 7X7 88E 8C1 8FI 8FJ 8FL 8R4 8R5 8V8 95. AAAUJ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AANZL AARHV AASML AATNV AAWTL AAYOK AAYQN AAYTO ABAKF ABDZT ABFTV ABIVO ABJNI ABJOX ABKCH ABKMS ABKTR ABOCM ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFO ACGFS ACHQT ACMJI ACMLO ACOKC ACPIV ACREN ACZOJ ADBBV ADFRT ADFZG ADHHG ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEYRQ AFALF AFBBN AFKRA AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHMBA AHSBF AIAKS AIGIU AILAN AIZAD AJRNO ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AQUVI ASPBG AVWKF AWSVR AXYYD AZFZN AZQEC A~4 BENPR BEZIV BGNMA BPHCQ BVXVI BYPQX C6C CAG CCPQU COF CS3 DCUDU DNIVK DPUIP DU5 DWQXO EBLON EBR EBS EBU EJD EMOBN ESX F5P FERAY FIGPU FLLZZ FNLPD FRNLG FSGXE FYUFA GNUQQ GROUPED_ABI_INFORM_RESEARCH HG6 HMCUK IAO IBB IEA IHR ITC IWAJR J-C J5H JZLTJ K1G K60 K6~ LGEZI LLZTM LOTEE M0C M0T M1P M2M M4Y NADUK NQJWS NU0 NXXTH OAC OPC OVD P2P PQBIZ PQBZA PQQKQ PROAC PSQYO PSYQQ Q2X RIG ROL RSV RZALA SISQX SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U9L UAX UG4 UKHRP UTJUX VDBLX VFIZW W48 WAF YFH YQY Z0Y Z7U ZMTXR ~JE AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY NPM 4T- 7XB 8FK K9. L.- L.0 PKEHL PQEST PQUKI Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c475t-76cbb075d98dd84fe595830cde3fe9d83fc58c73a7f941edcdce850d66f0957c3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001147734800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1170-7690 1179-2027 |
| IngestDate | Tue Nov 04 02:06:16 EST 2025 Fri Sep 05 10:30:35 EDT 2025 Fri Nov 07 23:22:27 EST 2025 Thu Apr 03 07:07:32 EDT 2025 Tue Nov 18 22:23:22 EST 2025 Sat Nov 29 02:10:26 EST 2025 Fri Feb 21 02:40:15 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-76cbb075d98dd84fe595830cde3fe9d83fc58c73a7f941edcdce850d66f0957c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-8121-4478 0000-0002-7608-1391 0000-0002-2702-3865 0000-0003-0513-0990 0000-0002-9003-994X 0000-0002-7500-6533 |
| OpenAccessLink | https://link.springer.com/10.1007/s40273-023-01342-y |
| PMID | 38267806 |
| PQID | 2957758528 |
| PQPubID | 43702 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10937761 proquest_miscellaneous_2918510266 proquest_journals_2957758528 pubmed_primary_38267806 crossref_citationtrail_10_1007_s40273_023_01342_y crossref_primary_10_1007_s40273_023_01342_y springer_journals_10_1007_s40273_023_01342_y |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-01 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: New Zealand – name: Auckland |
| PublicationTitle | PharmacoEconomics |
| PublicationTitleAbbrev | PharmacoEconomics |
| PublicationTitleAlternate | Pharmacoeconomics |
| PublicationYear | 2024 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. May 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-vol-26-no-2.pdf. Accessed 1 Nov 2022. Grinsztejn B, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083: efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services; 21 September 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed 1 Nov 2022. NeilanAMLandovitzRJLeMHGrinsztejnBFreedbergKAMcCauleyMCost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysisAnn Intern Med2022175447948910.7326/M21-1548350999929087297 Oglesby A, Germain G, Laliberte F, Bush S, Swygard H, MacKnight S, et al. Real-world persistency of patients receiving tenofovir-based pre-exposure prophylaxis for the prevention of HIV infection in the US. In: Presented at the Infectious Disease Week (IDWeek) Conference, Virtual. 29 Sep-3 Oct, 2021. Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2018. NCHS data brief no 355. Hyattsville, MD: National Center for Health Statistics; January 2020. https://www.cdc.gov/nchs/data/databriefs/db355-h.pdf. Accessed 1 Nov 2022. Delany-MoretlweSHughesJPBockPOumaSGHunidzariraPKalonjiDCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialLancet202239910337177917891:CAS:528:DC%2BB38XhsVOqsLzN10.1016/S0140-6736(22)00538-4353780779077443 KelleyCFKahleESieglerASanchezTDel RioCSullivanPSRosenbergESApplying a PrEP continuum of care for men who have sex with men in AtlantaGeorgia. Clin Infect Dis.201561101590159710.1093/cid/civ66426270691 ChenADowdyDWClinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-makingPLoS ONE201491010.1371/journal.pone.0108742252857934186823 WorkowskiKABachmannLHChanPAJohnstonCMMuznyCAParkISexually transmitted infection treatment guidelines, 2021MMWRR Recomm Rep.202170439 SchillieSWesterCOsburneMWesolowskiLRyersonABCDC recommendations for hepatitis C screening among adults—United States, 2020MMWR Morb Mortal Wkly Rep2020692117 CDC. Ending the HIV epidemic. April 1, 2021. https://www.cdc.gov/endhiv/index.html. Accessed 1 Nov 2022. HessKLHuXLanskyAMerminJHallHILifetime risk of a diagnosis of HIV infection in the United StatesAnn Epidemiol201727423824310.1016/j.annepidem.2017.02.003283255385524204 Landovitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083 final results: pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020. VemerPCorro RamosIvan VoornGAAlMJFeenstraTLAdViSHE: a validation-assessment tool of health-economic models for decision makers and model usersPharmacoeconomics20163443493611:STN:280:DC%2BC28vpsFOitg%3D%3D10.1007/s40273-015-0327-226660529 FarnhamPGGopalappaCSansomSLHutchinsonABBrooksJTWeidlePJUpdates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into careJ Acquir Immune Defic Syndr201364218318910.1097/QAI.0b013e318297396623615000 CDC. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Centers for Disease Control and Prevention; December 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed 1 Nov 2022. BeckEJMandaliaSLoGSharottPYouleMAndersonJCost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996–2006PLoS ONE2011651:CAS:528:DC%2BC3MXmvFCrsb0%3D10.1371/journal.pone.0020200216335143102104 CDC. Interpretation of hepatitis B serologic test results. https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf. Accessed 1 Nov 2022. CohenJPBeaubrunADingYWadeRLHinesDMEstimation of the incremental cumulative cost of HIV compared with a non-HIV populationPharmacoecon Open.20204468769610.1007/s41669-020-00209-8322197327688860 Moore M, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Hosseinipour M, et al. Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP. Presented at the The International AIDS Society (IAS), Virtual. 18–21 July, 2021. Available at: https://theprogramme.ias2021.org/Abstract/Abstract/1303. Accessed 25 Aug 2023. CDCUS Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline [Draft]2021Centers for Disease Control and Prevention CDC. Diagnoses of HIV infection in the United States and dependent areas, 2019. May 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 1 Nov 2022. MeraRScheerSCarterCDasMAsubontengJMcCallisterSBaetenJEstimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the metropolitan statistical area level in the United StatesJ Int AIDS Soc2019221210.1002/jia2.25433318601717086379 BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care200846434935610.1097/MLR.0b013e31815c31a718362813 MarrazzoJMRamjeeGRichardsonBAGomezKMgodiNNairGTenofovir-based preexposure prophylaxis for HIV infection among African womenN Engl J Med2015372650951810.1056/NEJMoa1402269256512454341965 NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness—the curious resilience of the $50,000-per-QALY thresholdN Engl J Med201437197967971:CAS:528:DC%2BC2cXhs12jtLnF10.1056/NEJMp140515825162885 TRUVADA PI. TRUVADA® (emtricitabine and tenofovir disoproxil fumarate) tablets, for oral use. Gilead Sciences; June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s061lbl.pdf. Accessed 1 Nov 2022. Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis. In: Presented at the AIDS Conference, Montreal, Canada and virtual. 29 July–2 August, 2022. MitchellKMBoilyMCHanscomBMooreMToddJPaz-BaileyGEstimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083Lancet Reg Health Am.202318368440119950652 CDC. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and preexposure prophylaxis (PrEP) data reported through December 2020. July 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-2-no-3/cdc-hiv-surveillance-tables-vol-2-no-3.pdf. Accessed 1 Nov 2022. DESCOVY PI. DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use. Gilead Sciences; January 2022. https://www.gilead.com/~/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf?la=en. Accessed 1 Nov 2022. SandersGDNeumannPJBasuABrockDWFeenyDKrahnMRecommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicineJAMA2016316101093110310.1001/jama.2016.1219527623463 US Bureau of Labor Statistics. Consumer price index for Medical Care. 2022. https://data.bls.gov/cgi-bin/surveymost?cu. Accessed Jan 2022. APRETUDE PI. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use. ViiV Healthcare; December 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf. Accessed 1 Nov 2022. GrantRMAndersonPLMcMahanVLiuAAmicoKRMehrotraMUptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyLancet Infect Dis201414982082910.1016/S1473-3099(14)70847-3250658576107918 MayerKMolinaJMThompsonMAAndersonPLMounzerKCDe WetJJEmtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialLancet2020396102462392541:CAS:528:DC%2BB3cXhsVKktr7F10.1016/S0140-6736(20)31065-5327118009665936 PaltielADFreedbergKAScottCASchackmanBRLosinaEWangBHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessClin Infect Dis200948680681510.1086/59709519193111 WalenskyRPHornTMcCannNCFreedbergKAPaltielADComparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis: a cost-effectiveness analysisAnn Intern Med2020172958359010.7326/M19-3478321506027217721 CMS.gov. Physician fee schedule. 1 July 2022. https://www.cms.gov/medicare/physician-fee-schedule/search/overview. Accessed 23 Aug 2022. LandovitzRJDonnellDClementMEHanscomBCottleLCoelhoLCabotegravir for HIV prevention in cisgender men and transgender womenN Engl J Med202138575956081:CAS:528:DC%2BB3MXhvVeqt7nI10.1056/NEJMoa2101016343799228448593 RossJStoverJUse of modern contraception increases when more methods become available: analysis CDC (1342_CR48) 2021 RP Walensky (1342_CR14) 2020; 172 S Delany-Moretlwe (1342_CR10) 2022; 399 EJ Beck (1342_CR36) 2011; 6 1342_CR20 1342_CR42 KL Hess (1342_CR16) 2017; 27 1342_CR45 1342_CR44 1342_CR40 P Vemer (1342_CR37) 2016; 34 RM Grant (1342_CR27) 2014; 14 1342_CR28 DP Serota (1342_CR22) 2020; 71 KM Mitchell (1342_CR41) 2023; 18 RS Braithwaite (1342_CR39) 2008; 46 S Torres-Rueda (1342_CR43) 2023; 41 K Mayer (1342_CR47) 2020; 396 RJ Landovitz (1342_CR9) 2021; 385 1342_CR24 1342_CR46 S Schillie (1342_CR19) 2020; 69 R Mera (1342_CR26) 2019; 22 J Ross (1342_CR25) 2013; 1 AM Neilan (1342_CR15) 2022; 175 JM Marrazzo (1342_CR4) 2015; 372 A Chen (1342_CR12) 2014; 9 CF Kelley (1342_CR23) 2015; 61 1342_CR1 C Celum (1342_CR5) 2021; 18 1342_CR2 1342_CR3 1342_CR6 1342_CR32 1342_CR7 1342_CR31 1342_CR8 1342_CR34 1342_CR11 1342_CR30 GD Sanders (1342_CR21) 2016; 316 1342_CR18 PG Farnham (1342_CR29) 2013; 64 1342_CR35 AD Paltiel (1342_CR13) 2009; 48 PJ Neumann (1342_CR38) 2014; 371 KA Workowski (1342_CR17) 2021; 70 JP Cohen (1342_CR33) 2020; 4 |
| References_xml | – reference: RossJStoverJUse of modern contraception increases when more methods become available: analysis of evidence from 1982–2009Glob Health Sci Pract.20131220321210.9745/GHSP-D-13-00010252765334168565 – reference: BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care200846434935610.1097/MLR.0b013e31815c31a718362813 – reference: SerotaDPRosenbergESSullivanPSThorneALRolleCMDel RioCPre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: a prospective cohort studyClin Infect Dis202071357458210.1093/cid/ciz89431499518 – reference: HessKLHuXLanskyAMerminJHallHILifetime risk of a diagnosis of HIV infection in the United StatesAnn Epidemiol201727423824310.1016/j.annepidem.2017.02.003283255385524204 – reference: Oglesby A, Germain G, Laliberte F, Bush S, Swygard H, MacKnight S, et al. Real-world persistency of patients receiving tenofovir-based pre-exposure prophylaxis for the prevention of HIV infection in the US. In: Presented at the Infectious Disease Week (IDWeek) Conference, Virtual. 29 Sep-3 Oct, 2021. – reference: VemerPCorro RamosIvan VoornGAAlMJFeenstraTLAdViSHE: a validation-assessment tool of health-economic models for decision makers and model usersPharmacoeconomics20163443493611:STN:280:DC%2BC28vpsFOitg%3D%3D10.1007/s40273-015-0327-226660529 – reference: CDC. US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Centers for Disease Control and Prevention; December 2021. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed 1 Nov 2022. – reference: MeraRScheerSCarterCDasMAsubontengJMcCallisterSBaetenJEstimation of new HIV diagnosis rates among high-risk, PrEP-eligible individuals using HIV surveillance data at the metropolitan statistical area level in the United StatesJ Int AIDS Soc2019221210.1002/jia2.25433318601717086379 – reference: CDC. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and preexposure prophylaxis (PrEP) data reported through December 2020. July 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-2-no-3/cdc-hiv-surveillance-tables-vol-2-no-3.pdf. Accessed 1 Nov 2022. – reference: CMS.gov. Physician fee schedule. 1 July 2022. https://www.cms.gov/medicare/physician-fee-schedule/search/overview. Accessed 23 Aug 2022. – reference: DESCOVY PI. DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use. Gilead Sciences; January 2022. https://www.gilead.com/~/media/files/pdfs/medicines/hiv/descovy/descovy_pi.pdf?la=en. Accessed 1 Nov 2022. – reference: CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. May 2021. https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-vol-26-no-2.pdf. Accessed 1 Nov 2022. – reference: WorkowskiKABachmannLHChanPAJohnstonCMMuznyCAParkISexually transmitted infection treatment guidelines, 2021MMWRR Recomm Rep.202170439 – reference: CohenJPBeaubrunADingYWadeRLHinesDMEstimation of the incremental cumulative cost of HIV compared with a non-HIV populationPharmacoecon Open.20204468769610.1007/s41669-020-00209-8322197327688860 – reference: MarrazzoJMRamjeeGRichardsonBAGomezKMgodiNNairGTenofovir-based preexposure prophylaxis for HIV infection among African womenN Engl J Med2015372650951810.1056/NEJMoa1402269256512454341965 – reference: Grinsztejn B, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083: efficacy of pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020. – reference: US Bureau of Labor Statistics. Consumer price index for Medical Care. 2022. https://data.bls.gov/cgi-bin/surveymost?cu. Accessed Jan 2022. – reference: NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness—the curious resilience of the $50,000-per-QALY thresholdN Engl J Med201437197967971:CAS:528:DC%2BC2cXhs12jtLnF10.1056/NEJMp140515825162885 – reference: CDC. Ending the HIV epidemic. April 1, 2021. https://www.cdc.gov/endhiv/index.html. Accessed 1 Nov 2022. – reference: PaltielADFreedbergKAScottCASchackmanBRLosinaEWangBHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessClin Infect Dis200948680681510.1086/59709519193111 – reference: Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis. In: Presented at the AIDS Conference, Montreal, Canada and virtual. 29 July–2 August, 2022. – reference: KelleyCFKahleESieglerASanchezTDel RioCSullivanPSRosenbergESApplying a PrEP continuum of care for men who have sex with men in AtlantaGeorgia. Clin Infect Dis.201561101590159710.1093/cid/civ66426270691 – reference: Delany-MoretlweSHughesJPBockPOumaSGHunidzariraPKalonjiDCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialLancet202239910337177917891:CAS:528:DC%2BB38XhsVOqsLzN10.1016/S0140-6736(22)00538-4353780779077443 – reference: TRUVADA PI. TRUVADA® (emtricitabine and tenofovir disoproxil fumarate) tablets, for oral use. Gilead Sciences; June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021752s061lbl.pdf. Accessed 1 Nov 2022. – reference: CDCUS Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline [Draft]2021Centers for Disease Control and Prevention – reference: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services; 21 September 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed 1 Nov 2022. – reference: BeckEJMandaliaSLoGSharottPYouleMAndersonJCost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996–2006PLoS ONE2011651:CAS:528:DC%2BC3MXmvFCrsb0%3D10.1371/journal.pone.0020200216335143102104 – reference: Sarri G, Soriano Gabarro M, Cheng R, Jhutti-Johal J. Gender and health equity in health care decision-making: how women’s issues continue to be neglected. In: Presented at: ISPOR Europe. Copenhagen, Denmark; 12–15 November 2023. – reference: ChenADowdyDWClinical effectiveness and cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men: risk calculators for real-world decision-makingPLoS ONE201491010.1371/journal.pone.0108742252857934186823 – reference: FarnhamPGGopalappaCSansomSLHutchinsonABBrooksJTWeidlePJUpdates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into careJ Acquir Immune Defic Syndr201364218318910.1097/QAI.0b013e318297396623615000 – reference: WalenskyRPHornTMcCannNCFreedbergKAPaltielADComparative pricing of branded tenofovir alafenamide-emtricitabine relative to generic tenofovir disoproxil fumarate-emtricitabine for HIV preexposure prophylaxis: a cost-effectiveness analysisAnn Intern Med2020172958359010.7326/M19-3478321506027217721 – reference: GrantRMAndersonPLMcMahanVLiuAAmicoKRMehrotraMUptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyLancet Infect Dis201414982082910.1016/S1473-3099(14)70847-3250658576107918 – reference: Torres-RuedaSTerris-PrestholtFGafosMIndravudhPPGiddingsRBozzaniFHealth economics research on non-surgical biomedical HIV prevention: identifying gaps and proposing a way forwardPharmacoeconomics202341778780210.1007/s40273-022-01231-w3690557010007656 – reference: CDC. Diagnoses of HIV infection in the United States and dependent areas, 2019. May 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 1 Nov 2022. – reference: MitchellKMBoilyMCHanscomBMooreMToddJPaz-BaileyGEstimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083Lancet Reg Health Am.202318368440119950652 – reference: Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2018. NCHS data brief no 355. Hyattsville, MD: National Center for Health Statistics; January 2020. https://www.cdc.gov/nchs/data/databriefs/db355-h.pdf. Accessed 1 Nov 2022. – reference: CDC. Interpretation of hepatitis B serologic test results. https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf. Accessed 1 Nov 2022. – reference: SandersGDNeumannPJBasuABrockDWFeenyDKrahnMRecommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicineJAMA2016316101093110310.1001/jama.2016.1219527623463 – reference: CelumCHosekSTsholwanaMKassimSMukakaSDyeBJPrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trialPLoS Med20211861:CAS:528:DC%2BB3MXhsFSjtLzN10.1371/journal.pmed.1003670341437798253429 – reference: MayerKMolinaJMThompsonMAAndersonPLMounzerKCDe WetJJEmtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialLancet2020396102462392541:CAS:528:DC%2BB3cXhsVKktr7F10.1016/S0140-6736(20)31065-5327118009665936 – reference: Landovitz RJ, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L. HPTN 083 final results: pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. In: Presented at the AIDS 2020 Conference, Virtual. 6–10 July, 2020. – reference: SchillieSWesterCOsburneMWesolowskiLRyersonABCDC recommendations for hepatitis C screening among adults—United States, 2020MMWR Morb Mortal Wkly Rep2020692117 – reference: APRETUDE PI. APRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use. ViiV Healthcare; December 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf. Accessed 1 Nov 2022. – reference: Moore M, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Hosseinipour M, et al. Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP. Presented at the The International AIDS Society (IAS), Virtual. 18–21 July, 2021. Available at: https://theprogramme.ias2021.org/Abstract/Abstract/1303. Accessed 25 Aug 2023. – reference: LandovitzRJDonnellDClementMEHanscomBCottleLCoelhoLCabotegravir for HIV prevention in cisgender men and transgender womenN Engl J Med202138575956081:CAS:528:DC%2BB3MXhvVeqt7nI10.1056/NEJMoa2101016343799228448593 – reference: Marzinke M, Grinsztejn B, Fogel J, Piwowar EM, Hanscom B, Coelho L. Laboratory analysis of HIV infections in HPTN 083: injectable CAB for PrEP [oral abstract]. In: Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts. 6–10 March, 2021. – reference: Merative Micromedex Solutions. Red Book. 2022. https://www.micromedexsolutions.com/home/dispatch/ssl/true. Accessed 15 Apr 2021. – reference: NeilanAMLandovitzRJLeMHGrinsztejnBFreedbergKAMcCauleyMCost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysisAnn Intern Med2022175447948910.7326/M21-1548350999929087297 – volume-title: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline [Draft] year: 2021 ident: 1342_CR48 – ident: 1342_CR11 – volume: 14 start-page: 820 issue: 9 year: 2014 ident: 1342_CR27 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70847-3 – volume: 9 issue: 10 year: 2014 ident: 1342_CR12 publication-title: PLoS ONE doi: 10.1371/journal.pone.0108742 – volume: 48 start-page: 806 issue: 6 year: 2009 ident: 1342_CR13 publication-title: Clin Infect Dis doi: 10.1086/597095 – ident: 1342_CR40 – volume: 70 start-page: 39 issue: 4 year: 2021 ident: 1342_CR17 publication-title: MMWRR Recomm Rep. – ident: 1342_CR34 – volume: 372 start-page: 509 issue: 6 year: 2015 ident: 1342_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1402269 – ident: 1342_CR32 – ident: 1342_CR30 – volume: 371 start-page: 796 issue: 9 year: 2014 ident: 1342_CR38 publication-title: N Engl J Med doi: 10.1056/NEJMp1405158 – volume: 41 start-page: 787 issue: 7 year: 2023 ident: 1342_CR43 publication-title: Pharmacoeconomics doi: 10.1007/s40273-022-01231-w – volume: 18 issue: 6 year: 2021 ident: 1342_CR5 publication-title: PLoS Med doi: 10.1371/journal.pmed.1003670 – ident: 1342_CR6 – volume: 27 start-page: 238 issue: 4 year: 2017 ident: 1342_CR16 publication-title: Ann Epidemiol doi: 10.1016/j.annepidem.2017.02.003 – volume: 175 start-page: 479 issue: 4 year: 2022 ident: 1342_CR15 publication-title: Ann Intern Med doi: 10.7326/M21-1548 – ident: 1342_CR8 – ident: 1342_CR44 – ident: 1342_CR46 – ident: 1342_CR42 – ident: 1342_CR2 – volume: 399 start-page: 1779 issue: 10337 year: 2022 ident: 1342_CR10 publication-title: Lancet doi: 10.1016/S0140-6736(22)00538-4 – volume: 18 year: 2023 ident: 1342_CR41 publication-title: Lancet Reg Health Am. – volume: 385 start-page: 595 issue: 7 year: 2021 ident: 1342_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101016 – ident: 1342_CR35 – volume: 4 start-page: 687 issue: 4 year: 2020 ident: 1342_CR33 publication-title: Pharmacoecon Open. doi: 10.1007/s41669-020-00209-8 – ident: 1342_CR18 – ident: 1342_CR31 – volume: 64 start-page: 183 issue: 2 year: 2013 ident: 1342_CR29 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3182973966 – volume: 69 start-page: 1 issue: 2 year: 2020 ident: 1342_CR19 publication-title: MMWR Morb Mortal Wkly Rep – volume: 61 start-page: 1590 issue: 10 year: 2015 ident: 1342_CR23 publication-title: Georgia. Clin Infect Dis. doi: 10.1093/cid/civ664 – volume: 396 start-page: 239 issue: 10246 year: 2020 ident: 1342_CR47 publication-title: Lancet doi: 10.1016/S0140-6736(20)31065-5 – ident: 1342_CR24 – ident: 1342_CR7 – volume: 71 start-page: 574 issue: 3 year: 2020 ident: 1342_CR22 publication-title: Clin Infect Dis doi: 10.1093/cid/ciz894 – ident: 1342_CR28 – ident: 1342_CR45 – ident: 1342_CR1 – volume: 172 start-page: 583 issue: 9 year: 2020 ident: 1342_CR14 publication-title: Ann Intern Med doi: 10.7326/M19-3478 – volume: 22 issue: 12 year: 2019 ident: 1342_CR26 publication-title: J Int AIDS Soc doi: 10.1002/jia2.25433 – ident: 1342_CR20 – volume: 6 issue: 5 year: 2011 ident: 1342_CR36 publication-title: PLoS ONE doi: 10.1371/journal.pone.0020200 – ident: 1342_CR3 – volume: 1 start-page: 203 issue: 2 year: 2013 ident: 1342_CR25 publication-title: Glob Health Sci Pract. doi: 10.9745/GHSP-D-13-00010 – volume: 316 start-page: 1093 issue: 10 year: 2016 ident: 1342_CR21 publication-title: JAMA doi: 10.1001/jama.2016.12195 – volume: 46 start-page: 349 issue: 4 year: 2008 ident: 1342_CR39 publication-title: Med Care doi: 10.1097/MLR.0b013e31815c31a7 – volume: 34 start-page: 349 issue: 4 year: 2016 ident: 1342_CR37 publication-title: Pharmacoeconomics doi: 10.1007/s40273-015-0327-2 |
| SSID | ssj0006372 |
| Score | 2.425102 |
| Snippet | Objective
Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of... Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring... Objective Cabotegravir long-acting (CAB-LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 447 |
| SubjectTerms | African Americans Antiretroviral drugs Cisgender Clinical trials Cost analysis Disease prevention Health Administration Health care industry Health Economics HIV Human immunodeficiency virus Immune system Infections Lifetime Medicine Medicine & Public Health Mutation Original Original Research Article Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Transgender persons |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB7BFgku_BQKgYKMhHphI7L5s32qyqpVkdAqQgX1FjmOTYOqZNlsq-6NV-AVeZKOHSerpaIXcotsK7FnPP5sz3wD8C7gQgjGjU-VoH6Mj1_gNsyPw0IFgdDm6scmm6CzGTs95Zk7cGudW2VvE62hLhtpzsg_hDyhBtuGbH_-0zdZo8ztqkuhcRe2DFNZPIKtj4ez7Mtgi9PIpm-y6VUobgRd2IwNnosNlYuPaxZup6M49FebS9MNvHnTbfKvu1O7JB09-t_OPIaHDoySg057nsAdVW_D_T5Wud2Gvaxjtl6Nyck6UKsdkz2SrTmvV0_hx7Rpl39-_e7cQ5wFJY0mU1QyS0hxWS3I56b-jpUOpPG1JgiXyfGnbyRbKNPyat6Y00p8bVD05-KqaklVEwSopAPGpAPGz-Dr0eHJ9Nh3aRx8GdNkieMuiwKRSclZWbJYq4QnLApkqSKteMkiLRMmaSSo5vEEh7c0qVSDMk014j8qox0Y1U2tXgDRNBAiwa5IhUhEap6qpOChQBTFsA33YNJLMJeO49yk2jjPB3ZmK_UcpZ5bqecrD94PbeYdw8ettXd7ieZutrf5WpwevB2KcZ6ayxdRq-bC1EFkhGguTT143unR8LkI93iUBVjCNjRsqGA4wDdL6urMcoEbNjBK04kH414Z1__17268vL0br-BBiOCt81DahdFycaFewz15uazaxRs3ya4BZAkzFQ priority: 102 providerName: ProQuest |
| Title | Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States |
| URI | https://link.springer.com/article/10.1007/s40273-023-01342-y https://www.ncbi.nlm.nih.gov/pubmed/38267806 https://www.proquest.com/docview/2957758528 https://www.proquest.com/docview/2918510266 https://pubmed.ncbi.nlm.nih.gov/PMC10937761 |
| Volume | 42 |
| WOSCitedRecordID | wos001147734800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: ABI/INFORM Collection customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: 7WY dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/abicomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ABI/INFORM Global customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: M0C dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/abiglobal providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: 7X7 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: M0T dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: M2M dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1179-2027 dateEnd: 20241208 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: 8C1 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Journals customDbUrl: eissn: 1179-2027 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006372 issn: 1170-7690 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-xDQES4qPjIzAqI6G9UEtpvuw8jmjTkGhVjTLKU-Q4DkSakqnppvW_52wnqcoACfpwUmSnjXtn--fc3e8A3rmxEILHOqZKMBrgh2Z4DKOBlynXFYV2_ZhiE2w65YtFPGuTwpou2r1zSZqVuk92CzT1CsU9Bo-_fuDR9Q7s4XbH9XQ8-3zer7-Rb0o2mZIqDA9_barM779jezu6hTFvh0r-4i8129DJ4_8bwBN41MJOcmTt5CncUdUA7ndZyc0A7k1aJ_sADmeWzno9IvNNdlYzIodktiG6Xg_goX3nR2wq0z7kSd2sqI0QaRdRUhckQTsznBTX5ZJ8qqvv9EjqYGuCeJmcfjwns6Wi6uay1i8r8aJGzV-Im7IhZUUQnxKLi4nFxc_gy8nxPDmlbRUHKgMWrlAFMssQmOQxz3MeFCqMQ-67Mld-oeKc-4UMuWS-YEUcjPGfznUlVTePogLhH5P-c9it6kq9BFIwV4gQhyEVAhFZxJEKs9gTCKI43hM7MO6UmcqW4lxX2rhIe3Jmo4MUdZAaHaRrB97391xago-_9j7obCRtJ3uTeviY-tjlcQfe9s04TbXvRVSqvtJ9EBghmIsiB15Yk-p_zscjHuMutvAtY-s7aArw7Zaq_GGowDUZGGPR2IFRZ3Ob5_rzMF79W_fX8MBDLGcDlg5gd7W8Um_grrxelc1yCDvs6zctF8xIjpIn4yHsfTiezs7wauImRs619CZDM19_AluNMxk |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL0qBalseJSXocAgQTfEwvFrZhYIVYEqUdMoi4C6c8fjMRhVdojTUu_4BX6Ej-JLuDN-RKGiuy7IzpoZJ-OcuXOu595zAV46XAjBuI6pEtT28WPH6IbZvhsrxxGpPvoxxSboZMKOjvh0A361uTA6rLK1icZQJ4XU78jfuDygmtu67N38m62rRunT1baERg2LA1V9R5etfDt6j__vK9fd_zAbDO2mqoAtfRosbRrKOMaNMuEsSZifqoAHzHNkorxU8YR5qQyYpJ6gKff7KpGJruzpJGGYIh2h0sP7XoPrWldPhxAeOrPO8oeeKRZlirlQdDubJB2Tqudr4Rgbd0h03j3ftav1jfACu70YpPnXSa3ZAPdv_2-P7g7caqg22avXxl3YUPk2bLWZ2OU27E5r3e6qR2arNLSyR3bJdKXoXd2Dr4OiXP7-8bMOfmn2B1KkZIBLyMhtnGULMi7yz9hpT-pIcoLOABmOPpHpQumR5_NCv4vFywKBfSLOs5JkOUH6TWraT2rafx8-XskzeQCbeZGrR0BS6ggR4FSkQp4lUx6qIOauQI7IcAy3oN8iJpKNgrsuJHISddrTBmURoiwyKIsqC153Y-a1fsmlvXdaBEWNLSujFXwseNE1oxXSR0siV8Wp7oO8D7lqGFrwsMZt93UeerCUOdjC1hDdddAK5-stefbFKJ1rrTNKw74FvRb8q9_172k8vnwaz2FrODscR-PR5OAJ3HSRptaxWDuwuVycqqdwQ54ts3LxzCxvAsdXvSj-AP1ekT0 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VgoALP-UvUMBI0AsbNZs_2weEqi2rrlqtciiot9RxHAiqkmWzLc2NV-B1eByehLGTbLRU9NYDe4tsZ9fZb-xv4plvAF47XAjBuI6pEtT28WMn6IbZvpsoxxGZPvoxxSbodMqOjni0Br-6XBgdVtmtiWahTkup35Fvuzygmtu6bDtrwyKi3fH72TdbV5DSJ61dOY0GIvuq_o7uW_Vusov_9RvXHX84HO3ZbYUBW_o0WNg0lEmCm2bKWZoyP1MBD5jnyFR5meIp8zIZMEk9QTPuD1UqU13l00nDMENqQqWH970G16mHKNZZ6qM-vCT0TOEoU9iFogvaJuyYtD1fi8jYuFuiI-_5rl2vbooXmO7FgM2_Tm3NZji--z8_xntwp6XgZKexmfuwpooNuNVlaFcbsBU1et71gBz26WnVgGyRqFf6rh_A11FZLX7_-NkExbT7BikzMkLTMjIcZ_mcHJTFZ-y0I3WEOUEngexNPpForvTI81mp39HiZYmAPxHneUXygiAtJ407QBp34CF8vJJn8gjWi7JQT4Bk1BEiwKlIhfxLZjxUQcJdgdyR4RhuwbBDTyxbZXddYOQkXmpSG8TFiLjYIC6uLXi7HDNrdE0u7b3ZoSlu17gq7qFkwatlM65O-shJFKo81X2QDyKHDUMLHjcYXn6dh54tZQ62sBV0Lzto5fPVliL_YhTQtQYapeHQgkFnCP3v-vc0nl4-jZdwE20hPphM95_BbRfZaxOitQnri_mpeg435Nkir-YvjKUTOL5qm_gDP6-Zuw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cost-effectiveness+of+Cabotegravir+Long-Acting+for+HIV+Pre-exposure+Prophylaxis+in+the+United+States&rft.jtitle=PharmacoEconomics&rft.au=Brogan%2C+Anita+J.&rft.au=Davis%2C+Ashley+E.&rft.au=Mellott%2C+Claire+E.&rft.au=Fraysse%2C+Jeremy&rft.date=2024-04-01&rft.pub=Springer+International+Publishing&rft.issn=1170-7690&rft.eissn=1179-2027&rft.volume=42&rft.issue=4&rft.spage=447&rft.epage=461&rft_id=info:doi/10.1007%2Fs40273-023-01342-y&rft.externalDocID=10_1007_s40273_023_01342_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1170-7690&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1170-7690&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1170-7690&client=summon |